Skip to main content
SpringerLink
Log in

Do recent reports of prolonged survival in patients with follicular lymphoma suggest that deferral of therapy is no longer justifiable?

  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

After an era in which it was unclear whether available systemic therapies for follicular lymphoma (FL) had influenced the survival of patients, several recent reports now suggest that survival of FL patients has improved over the past 25 years, presumably owing to expansion of therapeutic options. Has the pendulum swung so far that it is no longer justifiable to defer therapy in selected patients with FL? To date, the strongest evidence in support of treating all patients comes from randomized studies of different regimens suggesting that one offers a survival advantage over the other. The strongest evidence in support of deferring therapy for select patients comes from a few problematic randomized trials showing no difference between initial therapy and deferred therapy. The subset of patients with early-stage FL presents special but still inconclusive considerations. Accrual to prospective randomized trials is needed to answer the question.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Brandt L, Kimby E, Nygren P, Glimelius B: A systematic overview of chemotherapy effects in indolent non-Hodgkin’s lymphoma. Acta Oncol 2001, 40:213–223.

    PubMed  CAS  Google Scholar 

  2. Horning SJ: Natural history of and therapy for the indolent non-Hodgkin’s lymphomas. Semin Oncol 1993, 20:75–88.

    PubMed  CAS  Google Scholar 

  3. Horning SJ: Follicular lymphoma: Have we made any progress? [review]. Ann Oncol 2000, 11(suppl 1):23–27.

    Article  PubMed  Google Scholar 

  4. Johnson PW, Rohatiner AZ, Whelan JS, et al.: Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995, 13:140–147.

    PubMed  CAS  Google Scholar 

  5. Armitage JO, Cavalli F, Longo DL: Text Atlas of Lymphomas. Malden, MA: Blackwell Science; 1999.

    Google Scholar 

  6. Swenson WT, Wooldridge JE, Lynch CF, et al.: Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 2005, 23:5019–5026.

    Article  PubMed  Google Scholar 

  7. Fisher RI, LeBlanc M, Press OW, et al.: New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005, 23:8447–8452.

    Article  PubMed  CAS  Google Scholar 

  8. Liu Q, Fayad L, Cabanillas F, et al.: Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 2006, 24:1582–1589.

    Article  PubMed  Google Scholar 

  9. Solal-Celigny P, Lepage E, Brousse N, et al.: Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d’Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol 1998, 16:2332–2338.

    PubMed  CAS  Google Scholar 

  10. Rohatiner AZ, Gregory WM, Peterson B, et al.: Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 2005, 23:2215–2223.

    Article  PubMed  CAS  Google Scholar 

  11. Smalley RV, Weller E, Hawkins MJ, et al.: Final analysis of the ECOG I-COPA trial (E6484) in patients with non-Hodgkin’s lymphoma treated with interferon alfa (IFN-α2a) plus an anthracycline-based induction regimen. Leukemia 2001, 15:1118–1122.

    Article  PubMed  CAS  Google Scholar 

  12. Peterson BA, Petroni GR, Frizzera G, et al.: Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the Cancer and Leukemia Group B. J Clin Oncol 2003, 21:5–15.

    Article  PubMed  CAS  Google Scholar 

  13. Hiddemann W, Kneba M, Dreyling M, et al.: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005, 106:3725–3732.

    Article  PubMed  CAS  Google Scholar 

  14. Marcus RE, Solal-Celigny P, Imrie K, et al.: MabThera (rituximab) plus cyclophosphamide, vincristine and prednisone (CVP) chemotherapy improves survival in previously untreated patients with advanced follicular non-Hodgkins lymphoma (NHL) [abstract]. Blood (ASH Annual Meeting Abstracts) 2006, 108:146a (Abstract 481).

    Google Scholar 

  15. Salles GA, Foussard C, Mounier N, et al.: Rituximab added to αIFN+CHVP improves the outcome of follicular lymphoma patients with a high tumor burden: first analysis of the GELA-GOELAMS FL-2000 randomized trial in 359 patients [abstract]. Blood (ASH Annual Meeting Abstracts) 2004, 104:Abstract 160.

    Google Scholar 

  16. Herold M, Haas A, Srock S, et al.: Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007, 25:1986–1992.

    Article  PubMed  CAS  Google Scholar 

  17. Forstpointner R, Dreyling M, Repp R, et al.: The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004, 104:3064–3071.

    Article  PubMed  CAS  Google Scholar 

  18. Schulz H, Bohlius JF, Trelle S, et al.: Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007, 99:706–714.

    Article  PubMed  CAS  Google Scholar 

  19. Ganti AK, Weisenburger DD, Smith LM, et al.: Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience. Ann Oncol 2006, 17:920–927.

    Article  PubMed  CAS  Google Scholar 

  20. Wendum D, Sebban C, Gaulard P, et al.: Follicular largecell lymphoma treated with intensive chemotherapy: an analysis of 89 cases included in the LNH87 trial and comparison with the outcome of diffuse large B-cell lymphoma. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 1997, 15:1654–1663.

    PubMed  CAS  Google Scholar 

  21. Rigacci L, Federico M, Martelli M, et al.: The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: retrospective study of the Intergruppo Italiano Linfomi on 761 cases. Leuk Lymphoma 2003, 44:1911–1917.

    Article  PubMed  CAS  Google Scholar 

  22. Al-Tourah AJ, Gill KK, Hoskins PJ, et al.: The impact of initial treatment of advanced stage indolent lymphoma on the risk of transformation [abstract]. J Clin Oncol 2006, 24:424a (Abstract 7510).

    Article  Google Scholar 

  23. Ardeshna KM, Smith P, Norton A, et al.: Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003, 362:516–522.

    Article  PubMed  CAS  Google Scholar 

  24. Brice P, Bastion Y, Lepage E, et al.: Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 1997, 15:1110–1117.

    PubMed  CAS  Google Scholar 

  25. Kimby E, Bjorkholm M, Gahrton G, et al.: Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin’s lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. Ann Oncol 1994, 5(Suppl 2):67–71.

    PubMed  Google Scholar 

  26. Zinzani PL, Magagnoli M, Moretti L, et al.: Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma. J Clin Oncol 2000, 18:773–779.

    PubMed  CAS  Google Scholar 

  27. Young RC, Longo DL, Glatstein E, et al.: The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol 1988, 25:11–16.

    PubMed  CAS  Google Scholar 

  28. Chau I, Jones R, Cunningham D, et al.: Outcome of follicular lymphoma grade 3: Is anthracycline necessary as front-line therapy? Br J Cancer 2003, 89:36–42.

    Article  PubMed  CAS  Google Scholar 

  29. Dana BW, Dahlberg S, Nathwani BN, et al.: Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol 1993, 11:644–651.

    PubMed  CAS  Google Scholar 

  30. Armitage JO, Weisenburger DD: New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol. 1998, 16:2780–2795.

    PubMed  CAS  Google Scholar 

  31. Mac Manus MP, Hoppe RT: Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 1996, 14:1282–1290.

    PubMed  CAS  Google Scholar 

  32. Petersen PM, Gospodarowicz M, Tsang R, et al.: Long-term outcome in stage I and II follicular lymphoma following treatment with involved field radiation therapy alone [abstract]. J Clin Oncol 2004, 23:561a (Abstract 6521).

    Google Scholar 

  33. Vaughan Hudson B, Vaughan Hudson G, MacLennan KA, et al.: Clinical stage 1 non-Hodgkin’s lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. Br J Cancer 1994, 69:1088–1093.

    PubMed  CAS  Google Scholar 

  34. Kelsey SM, Newland AC, Hudson GV, Jelliffe AM: A British National Lymphoma Investigation randomised trial of single agent chlorambucil plus radiotherapy versus radiotherapy alone in low grade, localised non-Hodgkins lymphoma. Med Oncol 1994, 11:19–25.

    Article  PubMed  CAS  Google Scholar 

  35. Seymour JF, Pro B, Fuller LM, et al.: Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin’s lymphoma. J Clin Oncol 2003, 21:2115–2122.

    Article  PubMed  CAS  Google Scholar 

  36. Advani R, Rosenberg SA, Horning SJ: Stage I and II follicular non-Hodgkin’s lymphoma: long-term follow-up of no initial therapy. J Clin Oncol 2004, 22:1454–1459.

    Article  PubMed  Google Scholar 

  37. Soubeyran P, Eghbali H, Trojani M, et al.: Is there any place for a wait-and-see policy in stage I 0 follicular lymphoma? A study of 43 consecutive patients in a single center. Ann Oncol 1996, 7:713–718.

    PubMed  CAS  Google Scholar 

  38. The NCCN Follicular Lymphoma Grades 1–2 Clinical Practice Guidelines in Oncology (Version 2.2007). Available at http://www.nccn.org/professionals/physician_gls/PDF/nhl.pdf. Accessed June 2007.

  39. Hiddemann W, Dreyling M, Stahel RA: Minimum clinical recommendations for diagnosis, treatment and follow-up of newly diagnosed follicular lymphoma. Ann Oncol 2005, 16(suppl 1):i56–i57.

    Article  PubMed  Google Scholar 

  40. Friedberg JW, Huang J, Dillon H, et al.: Initial therapeutic strategy in follicular lymphoma (FL): an analysis from the National LymphoCare Study (NLCS) [abstract]. J Clin Oncol 2006, 24:Abstract 7527.

    Google Scholar 

  41. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 1993, 329:987–994.

  42. Lopez-Guillermo A, Montserrat E, Bosch F, et al.: Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol 1994, 12:1343–1348.

    PubMed  CAS  Google Scholar 

  43. Solal-Celigny P, Roy P, Colombat P, et al.: Follicular Lymphoma International Prognostic Index. Blood 2004, 104:1258–1265.

    Article  PubMed  CAS  Google Scholar 

  44. Cerhan J, Wang S, Maurer M, et al.: Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. Blood 2007, 109:5439–5446.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine & Holden Comprehensive Cancer Center, University of Iowa, 200 Hawkins Drive, C32 GH, Iowa City, IA, 52242, USA

    Brian K. Link

Authors
  1. Brian K. Link
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Brian K. Link.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Link, B.K. Do recent reports of prolonged survival in patients with follicular lymphoma suggest that deferral of therapy is no longer justifiable?. Curr Hematol Malig Rep 2, 219–224 (2007). https://doi.org/10.1007/s11899-007-0030-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-007-0030-2

Keywords

Search

Navigation